Pharmaceutical filing citing a Neurology paper — Catalyst Pharmaceuticals, 2024-03-13
Catalyst PharmaceuticalsCatalyst PharmaceuticalsUS CPRX
cited a paper published in Neurology as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past similar cases. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper like this in the press release
A periodic report submitted to the U.S. Securities and Exchange Commission when a listed company has something to inform its shareholders is called 8-K. The item numbers for Catalyst Pharmaceuticals' document filed on 2024-03-13 were 8.01 Other Events · 9.01 Financial Statements and Exhibits. The company cited a paper published in Neurology as the basis in the press release attached to it. The sentence citing the paper, copied verbatim from the original, is as follows.
References: [1] Dang UJ et al. (2024) Neurology 024;102:e208112. doi.org/10.1212/WNL.0000000000208112. Link . [2] Guglieri M et al (2022).
What a reader should first check is where the company placed the paper in the press release. Next, the reader should determine whether the paper supports the company's entire claim or only part of it. To answer the latter question, one must read the full paper. This article, which has only read the abstract, cannot provide an answer.
The scope of the paper discussed in the abstract is limited to this.
The paper's title is Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy and it was published in Neurology on 2024-02-09. The authors are affiliated with Veterans Affairs Canada. The summary at the beginning of the paper is called abstract. This article has read only up to this point. The paragraph was written by a person after filtering a draft generated by a machine reading the abstract through numerical comparison, and thus it is of a different grade than a full reading of the paper.
This is a 48-week trial of baricitinib in two doses for a young boy with Duchenne muscular dystrophy to reduce the side effects of steroids. The first half included a group receiving prednisone and a placebo group, while the second half continued with baricitinib for all. This paper discusses the second half. Children who switched from placebo to a high dose showed rapid improvement in motor function, while those who switched from prednisone showed varying degrees of improvement depending on the indicators. Safety was also assessed using growth rate and bone indicators, with the data provided in the main text.
What the abstract does not answer remains in the full paper and its appendices. This article, which has not gone beyond the abstract, leaves the gaps as they are. Readers should determine for themselves which sentence in the abstract corresponds to the excerpt cited by the company by comparing the two citations above.
One month later, the stock price was within the middle half of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. The date is written as trading day, counting only the days the stock market is open. In terms of the calendar, 20 trading days are approximately one month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | −1.5% | The extent of movement before the filing |
| On the day of the filing | +2.3% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | +3.0% | One week |
| Cumulative +1~+20 trading days | −6.6% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of -6.6% in this case is within the bottom 51% of the 142 samples, placing it in the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | −6.6% |
Half of the sample falls between the two central marks in the chart. One checks from the chart whether this case lies inside or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules to apply to the next case.
There is one additional case where the same company wrote a paper in 8-K, and it is placed together in the table below.
| Disclosure date | the journal of the paper | a month of excess return |
|---|---|---|
| 2024-02-21 | Neurology | +16.8% |
after the filing, the company issued such documents
after the filing date, the company issued three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content, so one can determine whether it was an earnings announcement or a contract by the number. The specific event is read in the original text of each link.
- 2024-05-08 8-K Item 8.01, 9.01 — Other Events · Financial Statements and Exhibits
- 2024-05-21 8-K Item 5.02,5.07 — Officer and Director Changes · Shareholder Meeting Results
- 2024-05-30 8-K Item 8.01, 9.01 — Other Events · Financial Statements · Exhibits
What This Article Does Not Answer
This article, which reads only the abstract, cannot answer what the paper re-examined, how, and to what extent. How many times the paper cited by the company was cited afterward can be verified again by the citation count from OpenAlexOpenAlex
Data source · Website. What will be seen next is whether the company's next 8-K again cites the same paper.
Term explanation
- 8-K
- A periodic report submitted to the Securities and Exchange Commission when a listed company in the United States has something to inform its shareholders. The type is indicated by item numbers such as earnings, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of the company alone by removing the portion where the market as a whole rises or falls.
- Trading day
- A date counted only on days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.